AI regulation
HIMSS25
Jonathan French, HIMSS' senior director of public policy, lays out the key points of HIMSS' response to the White House's request for information from the public on developing an AI action plan.
Two new memos update federal AI policy, which the White House says will accelerate innovation, strengthen public trust and prioritize U.S.-developed AI tools.
The lack of a strong set of AI-specific regulation in the U.S. allows innovation to happen quickly, but that also requires companies to be transparent and for the industry to take responsibility for its own actions, says Mika Newton, CEO of xCures.
Leaders of government public policy at HIMSS are prioritizing health equity, AI regulation, cybersecurity and workforce development while urging unified policies that support healthcare innovation.
The bill would allow AI to be classified as a "practitioner licensed by law" to administer FDA-approved drugs.
The EU guidelines highlight prohibitions on harmful manipulation, real-time biometric identification and social scoring.
President Trump revoked Joe Biden's 2023 order, which required HHS to establish an AI safety program and developers to share test results, among other directives.
At an event outside JPM, which included a representative from HHS, panelists discussed the government's role in advancing AI and the evolving healthcare landscape as a new administration transitions into power.
The Agency says AI can transform multiple aspects of healthcare, but it is difficult to fully oversee and regulate the technology without the assistance of all sectors involved.
The Act is the world's first major law for AI implementation and provides regulations for high-risk applications of the technology, including its use in healthcare.